Home / Business and Economy / Aspen Pharma Sees Earnings Surge 22%

Aspen Pharma Sees Earnings Surge 22%

2 Sep

Summary

Aspen Pharmacare reported a 22% rise in normalised earnings.
The commercial pharmaceuticals unit was the main growth driver.
Normalised headline earnings per share increased to 801.5 cents.

South Africa's Aspen Pharmacare has reported a notable 22% increase in its normalised earnings for the fiscal year ending June 30. This strong financial performance was predominantly fueled by robust momentum within its commercial pharmaceuticals division, which emerged as the key contributor to growth during the period.

Specifically, normalised headline earnings per share (HEPS) rose from 659.2 cents in the previous year to 801.5 cents for the current reporting period. The company also highlighted that on a constant exchange rate basis, HEPS experienced a significant appreciation of 28%.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.